Safety, Pharmacokinetics, and Immunomodulatory Effects of Lenalidomide in Children and Adolescents With Relapsed/Refractory Solid Tumors or Myelodysplastic Syndrome: A Children's Oncology Group Phase I Consortium Report

PURPOSE: To determine the maximum-tolerated or recommended phase II dose, dose-limiting toxicities (DLTs), pharmacokinetics (PK), and immunomodulatory effects of lenalidomide in children with recurrent or refractory solid tumors or myelodysplastic syndrome (MDS). PATIENTS AND METHODS: Cohorts of chi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Berg, Stacey L., Cairo, Mitchell S., Russell, Heidi, Ayello, Janet, Ingle, Ashish Mark, Lau, Henry, Chen, Nianhang, Adamson, Peter C., Blaney, Susan M.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2011
Matèries:
Original Reports
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3056465/
https://ncbi.nlm.nih.gov/pubmed/21149673
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.30.8387
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars